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 1. Introduction 
Attention-deﬁcit/hyperactivity disorder (ADHD) is a neu-
rodevelopmental condition that typically starts during
childhood or early adolescence and is thought to follow a
trait-like course. The clinical disorder is deﬁned by age-
inappropriate levels of inattention and/or hyperactivity-
impulsivity interfering with normal development, or
functioning, of a person. Although ADHD carries the stigma
of being a consequence of modern lifestyle, the ﬁrst
mentioning of the syndrome dates back to the late 18th
century ( Faraone et al., 2015 ). Historically, ADHD was de-
scribed mainly in school-age boys ( Still, 2006 ). Later, it wasPlease cite this article as: B. Franke et al., Live fast, die young? 
the lifespan, European Neuropsychopharmacology (2018), httpssearch, Karolinska Institutet, Stockholm, 
Norway 
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disorder (ADHD) is highly heritable and the most common neu-
ildhood. In recent decades, it has been appreciated that in a
disorder does not remit in puberty, but persists into adulthood.
d, ADHD is characterised by substantial comorbidity including
ty, and accidents. However, course and symptoms of the disor-
uctuate and change over time, and even age of onset in child-
ed. Available evidence to date is poor and largely inconsistent
 persistence versus remittance. Likewise, the development of
reseen early on, hampering preventive measures. These facts
n ADHD from childhood to old age. In this selective review, we
f the long-term course of ADHD, with an emphasis on clinical
ries, treatment effects over the lifespan, and the development
marise current knowledge and important unresolved issues on
fferent ADHD trajectories. We conclude that a severe lack of
in ADHD still exists for nearly every aspect reviewed. We en-
forts to overcome those knowledge gaps through appropriately
. 
recognised that many girls have similar problems – yet
often remain unrecognised and, consequently, undiag-
nosed. During the past decades, it has been demonstrated
that ADHD is common in all countries studied ( Fayyad
et al., 2017; Polanczyk et al., 2014 ), and that it seriously
affects the productivity, life expectancy, and quality of life
throughout the lifespan of patients ( Erskine et al., 2013 ).
Importantly, it took until the late 20th century before it
could convincingly be shown that ADHD also exists in adults,
and that continuity exists from childhood to adulthood
( Wood et al., 1976 ) calling for a lifespan perspective on theA review on the developmental trajectories of ADHD across 
://doi.org/10.1016/j.euroneuro.2018.08.001 
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Sisorder, embracing clinical course and presentation as well 
s according research on the underlying neurobiology. 
As discussed in detail in this review, the clinical presen-
ation of ADHD is very heterogeneous, with a wide spectrum
f severity and symptoms that partially overlap with other 
onditions. In fact, ADHD symptoms can be observed tran- 
iently not only in psychiatric disorders, but also in somatic 
iseases and physiological states, such as after sleep de- 
rivation or during over-exhaustion ( Poirier et al., 2016 ).
his complex clinical picture has led to a need to deﬁne
ore diagnostic attributes of ADHD, such as age of onset,
ontinuity of symptoms and their appearance under various 
ircumstances, symptom counts, and exclusion criteria. Al- 
hough the diagnostic criteria have been revised multiple 
imes, the core clinical description of ADHD has remained 
ssentially unchanged during several decades. In the latest 
ersion of the Diagnostic and Statistical Manual of Mental 
isorders (DSM-5), it is simply stated that “ADHD begins in 
hildhood” and that it often manifests itself in pre-school 
ge ( APA, 2013 ). This apparent simpliﬁcation does not imply
hat every person with ADHD will have an identical clinical 
icture, or that impairment is linearly dependent on symp- 
om counts or age of onset. 
Unfortunately, the ﬁelds of research on childhood and 
dulthood ADHD have operated in relative isolation, mainly 
ue to a historical hiatus between child/adolescent and 
dult psychiatry. However, the need for a lifespan perspec- 
ive is becoming increasingly apparent, and is enhanced by 
he voices of patients and their representatives (see e.g. the
extbox below). In this review, we present selected litera- 
ure to summarise the current knowledge on ADHD from a 
evelopmental, lifespan perspective. Preventive measures 
s well as age-speciﬁc diagnostics and interventions require 
nowledge about the highly dynamic changes in ADHD pre- 
entation from childhood to adulthood, and our review of 
he current state of knowledge is intended to provide re-
earchers and clinicians with an overview on the trajectory 
f this disorder. We focus on phenotypic changes across the
ifespan, age of onset issues (also covering the recent dis- 
ussion on adult onset ADHD), lifespan aspects of comorbid- 
ty, pharmacological and non-pharmacological treatment, 
s well as aspects of disease outcome with and without
reatment. In addition, we summarise knowledge on cogni- 
ive and neuroimaging changes during life with the disorder 
nd touch on lifespan aspects in the study of genetic and
nvironmental risk factors for the disorder as well as the in-
erplay of those two. Subsequent to these reviews, we point
ut existing knowledge gaps and identify needs for further 
esearch. 
extbox . The patient per specti ve – contributed by Andrea Bil-
ow, President of ADHD-Europe and Founder and Chief Exec- 
tive of the Attention Deficit Disorder Information and Support 
ervice (ADDISS) 
Despite considerable advances in our understanding of 
ADHD, patients still experience signiﬁcant problems 
gaining access to the support and treatment they need. 
Service user groups are established in most European 
countries. One of these groups, ADHD-Europe ( http: 
//www.adhdeurope.eu ), aims to advance the rights Please cite this article as: B. Franke et al., Live fast, die young? 
the lifespan, European Neuropsychopharmacology (2018), httpsof, and advocate on every level throughout Europe, 
for people affected by ADHD and comorbid conditions, 
helping them reach their full potential. ADHD-Europe 
plays a critical role in promoting awareness of ADHD 
and evidence-based treatments, facilitate the efforts 
of national and regional ADHD support groups, and ad- 
vocate to European Institutions for the delivery of ap- 
propriate services for children, adolescents, and adults 
with ADHD. 
Currently, the experience of service users is that 
they are often directed towards services that do not 
recognise the speciﬁc problems related to ADHD. This 
is a particular problem for adults with ADHD, although 
the quality and availability of child services also varies 
considerably across different countries and regions. 
Patients often feel there is nowhere to go for help 
with ADHD-related problems. In most cases, adult so- 
cial care does not yet cater for ADHD. At the same 
time, old age, learning disability, and mental health 
teams often do not consider ADHD as a mental health 
problem, which then falls between the cracks, with no 
service provision available. The lack of support con- 
tributes to people with ADHD experiencing more se- 
vere problems with age. When faced with challenges, 
they may feel overwhelmed and develop or exacer- 
bate comorbid problems such as anxiety, depression, 
and drug use, which then complicate ADHD. Much more 
work around social care and support is required. 
Even where there are health-care services for ADHD, 
the approach is often to use drugs alone without pro- 
viding the additional psychosocial support that is re- 
quired. In most cases, it is not enough to just see some- 
one and give a prescription. Health-care profession- 
als need to consider the environmental circumstances 
of each individual, and clinicians need to think “what 
more can I do for that person”. Practical support can 
come in many ways, but the key is to have a single 
person coordinating the treatment package – one who 
is aware of the individual circumstances and difﬁcul- 
ties faced by people being treated for ADHD and can 
provide practical support as required. 
Medication is viewed as an essential tool to ensure 
that other supports become effective. However, medi- 
cation often does not fully control all of the symptoms 
of ADHD, and most importantly, does not build skills. 
Organisational skills can improve with medication – be- 
ing less distracted and more able to stay on task and 
get things done – but people still need daily life skills. 
For example, someone may remain overwhelmed by 
tasks such as how to tidy up a room, how or organ- 
ise and complete paperwork, and how to plan ahead 
for the successful completion of tasks and ideas. 
Scaffolding and support for people with ADHD is 
complex and specialised. One of the problems is that 
support is often offered for short periods, such as 
3 months, but then they are on your own. Lifelong 
scaffolding and support may be required. To ﬁll the 
gap in service provision, a considerable amount of 
necessary practical and psychosocial support is cur- 
rently provided by the voluntary sector. One approach A review on the developmental trajectories of ADHD across 
://doi.org/10.1016/j.euroneuro.2018.08.001 
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 advocated by ADHD-Europe is to invest in the voluntary 
sector to provide the support services required, rather 
than rely on good-will of patient support groups. This 
is particularly important as the role of the voluntary 
sector is limited in what they can do due to lack of 
funding. 
2. Phenotype of ADHD across the lifespan –
course and changes in presentation over time 
ADHD is deﬁned as a persistent, trans-situational pattern
of inattention and/or hyperactivity-impulsivity that is inap-
propriate to the developmental stage and interferes with
functioning or development ( APA, 2013 ). Importantly, ADHD
symptoms as such do not reﬂect a manifestation of opposi-
tional behaviour, deﬁance, hostility, or failure to understand
tasks or instructions, although such problems are often seen
to accompany ADHD. Meta-analysis of longitudinal follow-up
studies of children with ADHD suggests that at least 15% con-
tinue to meet full diagnostic criteria for ADHD by the age of
25 years, and a further 50% meet criteria for ADHD in par-
tial remission, with persistence of subthreshold symptoms
still causing impairment ( Faraone et al., 2006 ). However,
there is considerable heterogeneity in those estimates, as
e.g. more recent estimates of persistence into young adult-
hood for children and adolescents diagnosed with DSM-IV
combined type ADHD in Europe are much higher (up to 80%)
( Cheung et al., 2015a; van Lieshout et al., 2016b ), perhaps
reﬂecting the severity of cases included in these studies,
and/or the use of informant- rather than self-ratings. 
Prevalence rates for ADHD in children range around
6.5% ( Polanczyk et al., 2007 ). Estimates for adults vary
widely across studies, but average around 2.5–3.4% in meta-
analysis ( Fayyad et al., 2007; Simon et al., 2009 ). Fayyad
et al. (2017) cite estimates ranging between 1.4 and 3.6%.
Such variation is almost certainly due to methodological
differences in the way the diagnostic criteria are applied,
including the childhood onset of symptoms, the methods
to capture the 18 behavioural symptoms used to deﬁne
the condition, and the application of impairment criteria
( Willcutt, 2012 ). Deﬁnitions of impairment are a particular
issue, because ADHD symptoms are known to be continually
distributed throughout the population, with no clear separa-
tion between those with and without ADHD ( Mulligan et al.,
2008 ). The disorder is therefore deﬁned by high levels of
symptoms when they interfere with or reduce the quality of
social, academic, or occupational functioning (NICE, 2013 ).
This might also at least in part underlie the discrepancy
between cross-sectional, epidemiological studies showing
adult ADHD prevalence rates almost as high as childhood
prevalence rates ( Fayyad et al., 2017 ), and longitudinal
samples that suggest adult prevalence rates to be much
lower ( Faraone et al., 2015 ). 
Characteristic changes occur in the proﬁle of ADHD
symptoms throughout development. Very young children
are more likely to display externalising symptoms such as
hyperactive-impulsive behaviour, while in middle childhood
inattentive symptoms become more apparent, and by latePlease cite this article as: B. Franke et al., Live fast, die young? 
the lifespan, European Neuropsychopharmacology (2018), httpsadolescence and in adulthood it is inattention that tends
to persist, while there is a decline in the more objective
signs of (motor) hyperactivity ( Francx et al., 2015b; Will-
cutt et al., 2012 ). Emotional lability, however, becomes a
growing burden, which can even dominate the clinical pic-
ture. It is this changing proﬁle and instability in the bal-
ance of symptoms presenting throughout development that
led to disbanding of the DSM-IV ADHD subtypes of predom-
inantly inattentive, predominantly hyperactive-impulsive,
and combined subtypes; those are now referred to as clin-
ical presentations in DSM-5. Although many adults present
with predominantly inattentive symptoms, this is not to
mean they have the same rate of hyperactive or impulsive
symptoms compared to age-matched controls. Persistence
of more overt hyperactivity-impulsivity is seen at higher
rates especially among those with some of the most se-
vere comorbid problems related to ADHD, such as substance
abuse and antisocial behaviour ( Huntley et al., 2012 ). 
Sex differences in the rates of ADHD are prominent but
change throughout development in both clinical and com-
munity settings ( Kooij et al., 2010; Larsson et al., 2011 ).
Typically, in child and adolescent clinics, around 80% of
ADHD cases are male, whereas in adult clinics, the propor-
tion of males is closer to 50% ( Kooij et al., 2010 ). One possi-
ble reason for the predominance of males in child clinics is
the greater hyperactivity-impulsivity levels they show com-
pared to girls, who are more likely to display predominantly
inattentive symptoms and less overt disruptive behaviours.
Several lines of evidence support this notion. For example,
an epidemiological survey of childhood ADHD found the ra-
tio of male to female cases was 7.0 for the hyperactive-
impulsive subtype, 4.9 for the combined subtype, and 3.0
for the inattentive subtype of ADHD. However, there was
still a greater percentage of boys with ADHD of any sub-
type (3.6%) compared to girls (0.85%). This is consistent
with mean scores for ADHD symptoms in general popula-
tion samples that show that, as a group, boys have higher
levels of both inattentive and hyperactive-impulsive symp-
toms than girls. Interestingly, by late adolescence, while
sex differences in inattention appear to remain, the level
of hyperactivity-impulsivity in boys declines to the level of
the girls ( Larsson et al., 2011 ), suggesting that the expres-
sion of core ADHD symptoms is more similar across the sexes
in the adult population. In addition to sex differences in the
expression of core ADHD symptoms, it is likely that comor-
bid problems contribute to different referral rates for boys
compared to girls, with boys presenting with more external-
ising disruptive behaviours and learning problems. In adults,
it is well known that women are more likely to seek help for
mental health problems, impacting on referral rates, but
levels of comorbid disorders appear to be similar in both
men and women with ADHD ( Biederman et al., 2004 ). 
While diagnostic criteria for ADHD originate from diag-
nosis of children, the currently used diagnostic criteria,
when applied to adults, are also well-validated and there-
fore appear to work well in the classiﬁcation of clinical
cases of the disorder ( Asherson et al., 2010 ). Validation of
the diagnostic criteria also requires the prediction of func-
tional and clinical impairments (NICE, 2018 ). Yet, most clin-
ical experts are aware of a broader expression of symp-
toms commonly reported by adults with ADHD ( Asherson
et al., 2016; Kooij et al., 2010 ) falling into three mainA review on the developmental trajectories of ADHD across 
://doi.org/10.1016/j.euroneuro.2018.08.001 
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Fig. 1 Theoretical developmental trajectories of ADHD across 
the lifespan. Details are given in the text. 
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h  ategories: age-adjusted expression of core ADHD symp- 
oms, behaviours reﬂecting problems with self-regulation 
executive functions), and additional problems that are 
ommonly seen in ADHD. Age-adjusted ADHD core symp- 
oms include some items in DSM-5 ( APA, 2013 ) and e.g.
nternal restlessness, ceaseless unfocused mental activity, 
nd a difﬁculty focusing on conversations. Problems with 
elf-regulation are e.g. problems with controlling impulses, 
witching attention, regulating emotional responses, initi- 
ting tasks, and problem-solving. Interestingly, while these 
re strongly correlated with the core ADHD symptoms of 
nattention and hyperactivity-impulsivity, they do not cor- 
elate strongly with neuropsychological tests of executive 
r top-down cortical control ( Barkley, 2010; Barkley and 
ischer, 2011 ), suggesting that, like core ADHD symptoms, 
hey result from deﬁcits across multiple neural networks 
nd cognitive processes. The additional problems seen in 
any adults include sleep problems and low self-esteem 
 Kooij et al., 2010 ). Furthermore, a study that carefully se-
ected adult ADHD cases with no evidence for a comorbid
isorder nevertheless found high rates of general mental 
ealth symptoms, such as subthreshold anxiety and depres- 
ion ( Skirrow and Asherson, 2013 ). 
. Age of onset and current discussion on 
dult onset of ADHD 
s pointed out above, ADHD has always been viewed as a
hildhood-onset condition, although the ﬁrst age at onset 
riterion was not seen until the advent of DSM-III, which 
equired onset prior to age 7 years ( APA, 1980 ). This thresh-
ld was raised to age 12 years in DSM-5 ( APA, 2013 ). Pa-
ients, however, can meet symptom and impairment crite- 
ia at later ages. Sometimes, such cases are clearly due to
rain injuries ( Fig. 1 ). If so, they are usually classiﬁed as
secondary” or “acquired” ADHD, to be distinguished from 
he childhood onset of ADHD discussed above ( Schachar 
t al., 2015 ). Longitudinal studies report a two-fold rela-
ive risk of receiving a diagnosis of ADHD after mild trau-Please cite this article as: B. Franke et al., Live fast, die young? 
the lifespan, European Neuropsychopharmacology (2018), httpsatic brain injury (TBI) ( Adeyemo et al., 2014 ); more severe
rain trauma carries an even higher risk for ADHD ( Schachar
t al., 2015 ). Overall, 15–50% of children with TBI develop
econdary ADHD ( Schachar et al., 2015 ), which may be clin-
cally indistinguishable from idiopathic ADHD. Because peo- 
le with ADHD are at risk for accidents ( Dalsgaard et al.,
015b ), ADHD may be a risk factor for head injuries ( Fann
t al., 2002 ), although this has been difﬁcult to establish
 Adeyemo et al., 2014 ). Nevertheless, it is possible that
ome patients with ADHD emerging subsequent to TBI had
ndiagnosed ADHD or subthreshold ADHD prior to their in-
ury. 
In contrast to the well-established link between TBI and
DHD in adulthood, the idea that idiopathic ADHD arises, de
ovo , in adulthood is controversial. Three population stud-
es estimated high rates of adult-onset idiopathic ADHD, 
ith a prevalence of 2.7% in New Zealand (NZ) ( Mofﬁtt
t al., 2015 ), 10.3% in Brazil ( Caye et al., 2016 ), and 5.5% in
he United Kingdom (UK) ( Agnew-Blais et al., 2016 ). The au-
hors concluded that ADHD can onset in adulthood and that
he adult-onset form of the disorder is categorically dis-
inct from the childhood-onset form. Yet these conclusions 
ere premature. All three studies had some serious limi-
ations ( Faraone and Biederman, 2016 ). Firstly, the age of
he adults in the studies from Brazil and the UK was only 18
o 19 years, so these studies provide no information about
ost of the adult period. Secondly, in all three studies, the
ates of childhood-onset adult ADHD were much lower than
xpected ( Fayyad et al., 2017 ), suggesting that many of the
hildhood-onset cases may have been missed and misdiag- 
osed as adult onset. Thirdly, all three studies suffer from
he “false positive paradox”, which is the mathematical fact
hat, in the absence of perfect diagnostic accuracy, many of
he diagnoses in a population study will be false positives.
or example, if the prevalence of adult ADHD is 5%, and the
alse positive rate is only 5%, then half of the adult ADHD
iagnoses in a population study will be false positives. Con-
istent with this idea, Sibley et al. (2017) concluded that
dult onset of ADHD is rare, and that most people exceeding
he symptom threshold for diagnosis are, on closer exami-
ation, false positives. A fourth caveat for the three studies
s that the distinction between childhood onset and adult-
ood onset was confounded by the method of diagnosis: the
ormer diagnoses were based on parent-report, whereas the 
atter were based on self-report. This is a problem, because
nother longitudinal study found that current symptoms of 
DHD were under-reported by adults who had ADHD in child-
ood and over-reported by adults who did not have ADHD
n childhood ( Sibley et al., 2012 ). Moreover, considerable
vidence suggests that, compared with informant-reports, 
elf-reports of ADHD in adults are less reliable. The noise
dded by self-reports can be seen in the very low heritabil-
ty for adult ADHD reported by the UK study (35%; Agnew-
lais et al., 2016 ), which contrasts with the higher heritabil-
ty of adult ADHD from parent report or using diagnostic cri-
eria ( Brikell et al., 2015 ). 
In all three studies, a participant was deﬁned as having
adult-onset” ADHD only if full diagnostic criteria for ADHD 
ad not been achieved at prior assessments. In each study,
owever, many of the “adult-onset” cases had evidence of 
sychopathology in childhood. In the NZ study, in their child-
ood years, the adult-onset ADHD group had more teacher-A review on the developmental trajectories of ADHD across 
://doi.org/10.1016/j.euroneuro.2018.08.001 
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 rated symptoms of ADHD, were more likely to have been di-
agnosed with conduct disorder (CD), and were more likely to
have had a combined parent-teacher report of ADHD symp-
tom onset prior to age 12 years ( Mofﬁtt et al., 2015 ). In
the UK study, the adult-onset cases had signiﬁcantly ele-
vated rates of ADHD symptoms, CD, and oppositional deﬁant
disorder (ODD) in childhood ( Agnew-Blais et al., 2016 ). In
the study from Brazil, only about a third of the adult-onset
cases were free of ADHD and CD symptomatology in child-
hood ( Caye et al., 2016 ). These population studies mirror
retrospective reports from referred cases, in which many
late adolescent and adult onset cases of ADHD had child-
hood histories of psychopathology ( Chandra et al., 2016 ). 
Faraone and Biederman (2016) suggested that apparent
cases of adult-onset ADHD are mostly due to the existence
of subthreshold childhood ADHD. For example, a prospec-
tive population study deﬁned “subthreshold ADHD” ( Fig. 1 )
as having three or more inattentive symptoms or three or
more hyperactive-impulsive symptoms ( Lecendreux et al.,
2015 ). It found that new-onset cases of ADHD in adolescence
were signiﬁcantly more likely to have had subthreshold
ADHD at baseline. In subthreshold cases, the onset of symp-
toms and impairment could be separated by many years,
particularly among those with supportive internal resources
(e.g., high intelligence) or supportive social environments. 
Given the issues discussed above, and until more evi-
dence is available, it seems best to refer to the adult-
onset cases reported by the studies from NZ, Brazil, and
the UK as apparent adult-onset ADHD (AAOA). An urgent
clinical question is whether stimulant treatment is appro-
priate for AAOA. This issue has not yet been systematically
assessed. From a clinical perspective, AAOA cases require
extra caution. Although many show signiﬁcant functional
impairments that require treatments for ADHD, some may
have other disorders. 
In conclusion, substantial research indicates that a diag-
nosable ADHD syndrome can arise in adulthood subsequent
to brain injury. Other forms of apparent adult-onset ADHD
may exist, but many of these are likely to have had undiag-
nosed ADHD or subthreshold ADHD in youth. 
4. Comorbidity proﬁle changes over time 
To complicate matters further, not only does the clinical
phenotype of ADHD change over the lifespan, but comor-
bid conditions might dominate the initial appearance of a
patient. This is of high relevance as ADHD patients fre-
quently suffer from psychiatric and non-psychiatric comor-
bid conditions, posing signiﬁcant clinical and public health
problems ( Angold et al., 1999 ). Throughout the lifespan,
the speciﬁc pattern of comorbidities changes substantially
( Costello et al., 2003; Taurines et al., 2010 ): in short, while
in children oppositional deﬁant disorder (ODD) and conduct
disorder (CD) are the most prevalent comorbid conditions,
substance use disorders (SUDs) become more and more of a
problem during adolescence and even more so in adulthood.
The comorbidity pattern of adult ADHD is highly diverse,
and in addition to SUDs encompasses mood and anxiety dis-
orders, antisocial personality disorder (ASP), sleep disor-
ders ( Jacob et al., 2007 ), as well as many somatic diseases
( Instanes et al., 2016 ). The developmental trajectory, riskPlease cite this article as: B. Franke et al., Live fast, die young? 
the lifespan, European Neuropsychopharmacology (2018), httpsfactors, and moderators of this lifelong comorbidity course,
however, are currently only poorly understood and require
future longitudinal studies. Below, information on the most
prominent ADHD comorbidities is given. 
4.1. Autism spectrum disorders, tics, and 
learning disorders 
ADHD and symptoms of autistic spectrum disorders (ASDs)
often co-exist, as 20–50% of children with ADHD also meet
criteria for ASDs ( Rommelse et al., 2011 ). Several studies
have shown social deﬁcits, peer relationship, and empa-
thy problems to be common in ADHD, and accordingly, the
DSM-5 ﬁnally allows a comorbid diagnosis of ADHD and ASD.
The ADHD-ASD comorbidity has mainly been studied in chil-
dren; a review and meta-analysis, however, support its ex-
istence also in adults ( Hartman et al., 2016 ). Recent data
from a large, register-based study from Sweden suggest that
the comorbidity has its roots in shared genetic/familial fac-
tors ( Ghirardi et al., 2017 ). Tic disorders occur in up to
3–4% of the population ( Robertson et al., 2009; Roessner
et al., 2011 ) and are seen in 10 to 20% of children with
ADHD ( Cohen et al., 2013; Steinhausen et al., 2006 ). Over
the course of years, tic severity typically peaks between
8 and 12 years of age. The natural history of tics usually
shows a marked decline during adolescence ( Cohen et al.,
2013 ). Population studies suggest that intellectual disabil-
ity may be more common (up to 5–10 times) in ADHD than
in children without ADHD ( Simonoff et al., 2007 ). About 25–
40% of all patients with ADHD have major reading and writ-
ing difﬁculties, and many show co-existing language disor-
ders ( Sciberras et al., 2014; Willcutt et al., 2012 ). Similarly,
there is a considerable overlap between ADHD and disor-
ders of arithmetical skills ( Hart et al., 2010; Rapport et al.,
1999 ). As for ASD, hardly any information is yet available on
the lifespan trajectories of ADHD with such comorbidities. 
4.2. Rule-breaking behaviours 
The comorbidity of ADHD with antisocial behaviours is of
particular societal relevance, as ADHD seems to convey an
increased risk for violence and incarceration especially in
the context of such comorbidity ( Rosler et al., 2004 ). In
children and adolescents, both clinical and epidemiological
studies show a high prevalence of comorbidity of ADHD with
ODD/CD, ranging from 25% up to 80% (median odds ratio
(OR): 10) in different studies. ODD and CD predict a more
severe clinical symptomatology, more severe functional im-
pairments, higher persistence of ADHD into adulthood, and
worse outcome of the disorder. They also mediate the risk
for the development of other problems, such as substance
use and depression ( Burke et al., 2002; Hill, 2002 ). Comor-
bid ODD in childhood seems to also increase the risk for
CD/ASP and depression in ADHD later in life, and comor-
bid CD does even more ( Biederman et al., 2008; Mannuzza
et al., 2004 ). Increased impulsivity may be an important
risk factor within the ADHD group for these negative out-
comes ( Retz and Rosler, 2009; Storebo and Simonsen, 2016 ).
However, ADHD-affected children without these comorbidi-
ties may also develop antisocial behaviours later in lifeA review on the developmental trajectories of ADHD across 
://doi.org/10.1016/j.euroneuro.2018.08.001 
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s   Jensen et al., 1997; Loeber et al., 1995; Mannuzza et al.,
004 ). SUDs and environmental variables might be impor- 
ant moderators in this, although this has yet to be formally
stablished. 
.3. Substance use disorders 
nother (related) issue of importance in ADHD across the 
ifespan is the liability to develop addictions. The earlier 
nset and increased use of tobacco, alcohol, and illicit sub- 
tances in adolescents with ADHD compared to controls has 
een demonstrated in various studies, and a high preva- 
ence of drug abuse or dependency (9–40%) is also reported
n adulthood ( Buchmann et al., 2009; Jacob et al., 2007;
annuzza et al., 1993; Milberger et al., 1997 ). A meta-
nalysis of cohort studies conﬁrmed that childhood ADHD 
igniﬁcantly increases the risk for nicotine use in middle 
dolescence (OR: 2.36, 1.71–3.27) and the risk for alcohol 
se disorder during young adulthood (OR: 1.35, CI: 1.11–
.64) ( Charach et al., 2011 ). This meta-analysis also sug-
ested that children with ADHD may have an elevated risk 
or cannabis use and psychoactive substance use as young 
dults, but signiﬁcant heterogeneity exists between studies, 
nd the association with drug use disorder was highly inﬂu-
nced by a single study. As another meta-analysis showed, 
ontrolling for comorbid disorders (particularly CD) substan- 
ially weakened the association between ADHD and SUDs; 
n fact, it could not be conﬁrmed that ADHD increases the
isk for SUDs beyond the effects of CD/ODD ( Serra-Pinheiro
t al., 2013 ). Looked at from the other side, in adult pa-
ients suffering from alcohol abuse, 30–70% suffered from 
hildhood ADHD, and 15–25% still displayed the disorder as 
dults. 
.4. Mood and anxiety disorders 
dult ADHD is signiﬁcantly comorbid with anxiety disorders 
up to 25%; median OR: 3.0) and major depression (5–20%;
edian OR: 5.5). Although these disorders are among the 
ost common comorbidities of ADHD, especially in adoles- 
ents ( Meinzer et al., 2013 ) and adults ( Jacob et al., 2007 ),
urprisingly little is known about the developmental trajec- 
ories of such comorbidity. As mentioned above, ODD/CD 
eem to be associated with later-life affective disorders; 
lso, depressive and anxious symptoms during childhood and 
dolescence go along with increased risk for adult-life de- 
ression (as do general risk factors for depression), although 
ften no such antecedents can be found in adult ADHD with
epression. Rather, childhood ADHD itself seems to be a 
isk factor for the later development of depression, which 
an be reduced by e.g. methylphenidate treatment ( Chang 
t al., 2016 ). 
.5. Disruptive mood dysregulation disorder and 
ipolar disorder 
n issue of increasing interest in research and clinic is the
resence of extreme and uncontrolled emotional and mood 
hanges in both children and adults with ADHD. Indeed, in Please cite this article as: B. Franke et al., Live fast, die young? 
the lifespan, European Neuropsychopharmacology (2018), httpsSM-5, problems with emotion regulation are listed as char-
cteristic features of ADHD that support the diagnosis. Emo-
ional dysregulation and ADHD are known to share genetic
isks ( Merwood et al., 2014 ). In adult ADHD, emotional dys-
egulation occurs also in the absence of comorbid disorders
 Skirrow and Asherson, 2013 ), is an independent predictor
f impairment ( Barkley and Fischer, 2010; Skirrow and Ash-
rson, 2013 ), and responds to both stimulants and atomox-
tine ( Moukhtarian et al., 2017 ). In some cases, specialist
eferral is advised to ensure accurate diagnosis, because 
he problems may be complex and predictive of particu-
ar adverse outcomes ( Sobanski et al., 2010; Stringaris and
oodman, 2009 ). Comorbidity with bipolar disorder and bor-
erline personality disorder both need to be considered in
dults, since ADHD may co-exist with these conditions, but
ay also mimic them in the presence of severe emotional
ysregulation ( Asherson et al., 2016 ). Cross-sectional epi-
emiological studies as well as family-based studies show 
hat there is increased comorbidity between bipolar disor- 
er and current or lifetime ADHD; mutual comorbidity rates
re around 20% ( Kessler et al., 2006 ). The developmen-
al trajectories of this comorbidity are unclear, however, 
ince bipolar disorder is rare in pre-adolescents, even when
evere irritability and anger are prominent in this group
 Brotman et al., 2006 ). The new DSM-5 diagnosis “disrup-
ive mood dysregulation disorder (DMDD)” for children up to 
ge 8 years exhibiting persistent irritability, intolerance to 
rustration, and frequent episodes of extreme behavioural 
yscontrol captures those symptoms, yet the course of this
yndrome into full-blown bipolar disorder is far from estab-
ished. Importantly, most of the DMDD patients also meet
riteria for ADHD. 
. Treatment and response to treatment 
ver time – pharmacological and 
on-pharmacological treatments 
he continuity of treatment of ADHD across the lifespan is
n issue that still receives too little attention. Especially the
ransition from adolescence to adulthood, which is accom- 
anied by a transition from child and adolescent psychiatric
linics to adult psychiatry, is problematic; many patients are
ost to follow up at that point. At every age, recommended
reatment of ADHD should be multimodal, including psycho- 
ducation, pharmacotherapy, and disorder-oriented psy- 
hotherapy, including training, cognitive-behavioural ther- 
py, and family or couple therapy if needed ( Faraone et al.,
015; Kooij et al., 2010 ; NICE, 2018 ). 
Pharmacological treatments with the indication for ADHD 
re traditionally divided into two groups: stimulants and 
on-stimulants. Methylphenidate and amphetamines are 
he stimulant options, and atomoxetine, guanfacine, and 
lonidine are the non-stimulants ( Faraone et al., 2015 ). The
ame drugs are used across the lifespan in clinical prac-
ice, but only methylphenidate, lisdexamfetamine, and ato- 
oxetine are ofﬁcially approved for treatment of ADHD 
n childhood and adulthood in most European countries 
 Ramos-Quiroga et al., 2013 ). Unsurprisingly, there have
een many more clinical trials evaluating the efﬁcacy and
afety of these drugs in children than in adults ( FaraoneA review on the developmental trajectories of ADHD across 
://doi.org/10.1016/j.euroneuro.2018.08.001 
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Table 1 Reported effect sizes (standardised mean difference) from meta-analysis for studies of treatment efﬁcacy for ADHD 
core symptoms in childhood and adulthood. 
Treatment and age-group Treatment type Effect size Reference 
Childhood: pharmacological 
treatment 
Methylphenidate 0.72 Faraone and Buitelaar (2010) 
Amphetamines 0.99 Faraone and Buitelaar (2010) 
Atomoxetine 0.64 Schwartz and Correll (2014) 
Guanfacine 0.63 Hirota et al. (2014) 
Clonidine 0.44 Hirota et al. (2014) 
Childhood: non-pharmacological 
treatment 
Omega-3 0.16 Sonuga-Barke et al. (2013) 
Diets 0.42 Sonuga-Barke et al. (2013) 
Neurofeedback 0.21 Hodgson et al. (2014) 
Multimodal psychosocial 0.09 Hodgson et al. (2014) 
Working memory training −0.02 −0.20 Cortese et al. (2015) ; Hodgson 
et al. (2014) 
Behaviour modiﬁcation −0.03 Hodgson et al. (2014) 
Parent training −0.51 Hodgson et al. (2014) 
Self-monitoring −5.91 Hodgson et al. (2014) 
School-based −0.26 −0.16 Hodgson et al. (2014) ; Richardson 
et al. (2015) 
Adulthood: pharmacological 
treatment 
Methylphenidate 0.42 −0.72 Castells et al. (2011b; Epstein 
et al. (2014 
Amphetamines 0.72 −1.07 Castells et al. (2011a) ; Fridman 
et al. (2015) 
Atomoxetine 0.38 −0.60 Asherson et al. (2014) ; Fridman 
et al. (2015) 
Adulthood: non-pharmacological 
treatment 
Cognitive-behavioural therapy 0.43 −1.0 Jensen et al. (2016) ; Knouse et al. 
(2017) ; Young et al. (2016) 
Mindfulness-based therapies 0.53 −0.66 Cairncross and Miller (2016) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 and Buitelaar, 2010; Fridman et al., 2015 ). Nevertheless,
randomised, placebo-controlled clinical trials and meta-
analyses convincingly show the effectiveness and safety of
both stimulant and non-stimulant drugs for ADHD also in
adults ( Epstein et al., 2014; Fridman et al., 2015 ) ( Table 1 ).
The National Institute for Health and Clinical Excellence
(NICE) guidelines recommend pharmacotherapy as ﬁrst-
line treatment for adult ADHD (NICE, 2018 ) and consider
methylphenidate as the ﬁrst choice for the treatment of
adults, based on available meta-analytical evidence. Ap-
parent differences in the effect size for methylphenidate
across the lifespan are likely due to different dosing reg-
imens applied in the clinical trials. Doses around 1 mg/kg
of methylphenidate are correlated with better efﬁcacy, yet
are rarely achieved in studies of adult patients. Regard-
ing amphetamines or atomoxetine, the situation is similar;
highest doses are related with best efﬁcacy. Another fac-
tor that may explain the discrepancies in effect sizes is
the presence of comorbid disorders. As an example, stud-
ies that included patients with SUDs have shown compar-
atively smaller effect sizes. The inﬂuence of such comor-
bidities on treatment outcome is not exclusively observed
in pharmacological trials, the same is seen for studies of
non-pharmacological treatments. 
In terms of drug treatment side effects, the most typi-
cal are decreased appetite, sleep disturbance, headaches,
drowsiness, tearfulness, abdominal discomfort, nausea and
vomiting, irritability, mood changes, constipation, fatigue,Please cite this article as: B. Franke et al., Live fast, die young? 
the lifespan, European Neuropsychopharmacology (2018), httpssedation, and increased blood pressure and pulse. Delays
in height and weight are relatively minor with stimulants,
often appear to attenuate with time, and seem not to af-
fect ultimate height and weight in adulthood ( Fredriksen
et al., 2013 ). The cardiovascular safety of stimulant med-
ications and atomoxetine has been a subject of debate over
many years. It is quite surprising that this controversy occurs
for drugs such as methylphenidate, which have been on the
market for over 50 years. Cohort studies, however, did not
ﬁnd an increase in serious cardiovascular events following
ADHD medications in children or adults, although both stim-
ulants and atomoxetine were found associated with slight
increases in heart rate and blood pressure ( Cooper et al.,
2011 ). 
Public concerns that stimulant treatment in childhood
and adolescence may increase SUDs in adulthood seem un-
substantiated. A comprehensive meta-analysis of long-term
studies indicates comparable outcomes between children
with and without medication treatment history for any sub-
stance use and abuse or dependence outcome across all sub-
stance types ( Hamshere et al., 2013 ); accordingly, Scandina-
vian registry studies ( Chang et al., 2014b; Dalsgaard et al.,
2014 ) found that ADHD medication was not associated with
increased rate of substance abuse; if anything, the data sug-
gested a long-term protective effect on substance abuse
( Chang et al., 2014b ) (see below). 
Research of pharmacotherapy in adults with ADHD is still
largely lacking, especially with respect to clinical trialsA review on the developmental trajectories of ADHD across 
://doi.org/10.1016/j.euroneuro.2018.08.001 
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c  omparing different treatments (pharmacological or psy- 
hological) head to head as done in a pioneering study 
 Philipsen et al., 2015 ). At the same time, it is necessary to
mprove the external validity of these studies. Most of the
xisting clinical trials in this area are the ones performed
o reach indication for adults for a particular drug. These 
tudies used very restrictive inclusion and exclusion crite- 
ia, rarely reﬂecting real-life patients. A second area, in 
hich more research is needed, is the systematic assess- 
ent of the efﬁcacy and safety of ADHD treatment in the
resence of comorbid disorders, especially psychosis. Fi- 
ally, it is known that around 30% of ADHD patients do not
espond to currently available treatments ( Faraone et al., 
015 ). It is therefore important to investigate new pharma-
ological targets beyond the dopaminergic and noradrener- 
ic systems, preferably including new knowledge on the bi- 
logical pathways involved in ADHD aetiology (see below). 
ne line of evidence comes from a trial of low dose cannabi-
oids, which found moderate to large effects on core ADHD
ymptoms in the absence of adverse effects; this study im-
licates the cannabinoid system as a potential new target 
or drug development ( Cooper et al., 2017 ). 
It is important to highlight the positive impact of ADHD
reatment on aspects of daily functioning. Although initial 
tudies were disappointing regarding the longer-term ef- 
ects of treatment ( Molina et al., 2009 ), the studies from
candinavian registries impressively document positive out- 
omes of treatment, as discussed below. 
In addition to pharmacotherapy, several non- 
harmacological approaches are used in the control and 
anagement of ADHD across the lifespan ( Table 1 ). In many
ountries, for children and adolescents with mild ADHD, 
on-pharmacological interventions are the ﬁrst-line treat- 
ent. In moderate or severe cases, the recommendation is 
o combine non-pharmacological treatment and drug treat- 
ent ( Faraone et al., 2015 ). Thus far, non-pharmacological
reatments in childhood have demonstrated lesser efﬁcacy 
n reducing ADHD core symptoms than ADHD drugs ( Sonuga-
arke et al., 2013 ), but may have important beneﬁts for
o-occurring comorbidities and behavioural problems. In 
act, only free fatty acid supplementation and exclusion 
f artiﬁcial food colour from the diet demonstrated sig- 
iﬁcant beneﬁcial effects on ADHD core symptoms during 
hildhood in a rigorous meta-analysis, although the effects 
ere relatively small ( Chronis et al., 2006 ; Nutt et al.,
007; Philipsen, 2012; Sonuga-Barke et al., 2013; Young 
t al., 2015 ). Although cognitive-behavioural therapy (CBT) 
pproaches have not been proven efﬁcacious in children 
 Sonuga-Barke et al., 2013 ), the ﬁrst studies have reported
hat individual CBT ( Antshel et al., 2014 ) and group CBT
 Vidal et al., 2015 ) could be effective treatments for
dolescents with ADHD. 
Of particular importance is the transition from child- 
ood to adult services, requiring continuation of both med- 
cal and psychological support ( Nutt et al., 2007 ). As in-
icated above, for adults, pharmacological treatment is 
he recommended ﬁrst choice. Group CBT has been proven 
o beneﬁt adults with ADHD ( Solanto et al., 2010 ), but
ne study showed that highly structured group interven- 
ion did not outperform individual clinical management 
ith unstructured support with regard to the core ADHD 
ymptoms ( Philipsen et al., 2015 ). Promising ﬁndings also Please cite this article as: B. Franke et al., Live fast, die young? 
the lifespan, European Neuropsychopharmacology (2018), httpsaise the possibility of mindfulness-based interventions as 
n effective treatment for ADHD symptoms ( Cairncross and
iller, 2016; Hepark et al., 2015 ). For other types of non-
harmacological treatments, such as neurofeedback, more 
vidence for efﬁcacy from randomised clinical trials with 
linded assessment is necessary for both adolescents and 
dults ( Cortese et al., 2016 ). 
. Disease outcome with and without 
reatment 
ssessment of disease outcome in ADHD requires longitu- 
inal study designs, which are generally scarce. As a re-
ult, also the knowledge about the role of treatment during
he different phases of life in such outcomes is still patchy.
ome clinically-based studies of high quality that have fol-
owed up pre-adolescents with ADHD into adulthood are al-
eady available and have been instrumental in documenting 
he disease outcomes of ADHD in different aspects of life.
hose include academic, occupational, and social aspects 
s well as morbidity and mortality. It has been shown that
DHD is associated with academic outcomes, such as poor
cademic performance (e.g., lower grade point average and 
ncreased rates of grade retention) ( Galera et al., 2009 ) and
ower rates of high-school graduation and post-secondary 
ducation ( Galera et al., 2009; Klein et al., 2012; Man-
uzza et al., 1993 ). ADHD is also associated with negative
ccupational outcomes such as unemployment ( Biederman 
t al., 2006; Klein et al., 2012 ), having trouble keeping
obs ( Barkley et al., 2006; Biederman et al., 2006 ), ﬁnan-
ial problems ( Barkley et al., 2006; Klein et al., 2012 ),
nd work incapacity in terms of sickness absence ( Kleinman
t al., 2009; Secnik et al., 2005 ). Those studies have also
hown that individuals with ADHD are at increased risk for
oor social outcomes such as high rates of separation and
ivorce ( Biederman et al., 2006; Klein et al., 2012 ), resi-
ential moves ( Barkley et al., 2006 ), and early parenthood
 Barkley et al., 2006 ). 
In terms of mortality, several studies from Scandinavia 
ave explored the association of ADHD with mortality and
hich factors are likely to increase mortality. These stud-
es have used information from national registers in Swe-
en and Denmark that have been linked using a unique
erson identiﬁer. A Danish register-based study has found 
hat ADHD is associated with signiﬁcantly increased mortal- 
ty rates, and that the excess mortality in ADHD is mainly
riven by deaths from unnatural causes, especially acci- 
ents ( Dalsgaard et al., 2015b ). Other register-based stud-
es have conﬁrmed that individuals with ADHD are at in-
reased risk for serious transport accidents ( Chang et al.,
014a ), and also show increases in criminality ( Dalsgaard
t al., 2013; Lichtenstein et al., 2012 ) and suicidal be-
aviour ( Ljung et al., 2014 ), which are severe negative out-
omes in their own right and could contribute to the in-
reased mortality. 
Systematic reviews of the long-term disease outcomes of 
reated versus untreated ADHD are somewhat inconsistent. 
his is partly because long-term observational studies are 
ften limited by a lack of data about treatment compliance
nd can be confounded by indication, since more severe
ases will be more likely to be treated. A systematic reviewA review on the developmental trajectories of ADHD across 
://doi.org/10.1016/j.euroneuro.2018.08.001 
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 of randomised controlled trial open-label extension stud-
ies and naturalistic studies of adults with ADHD concluded
that ADHD medications have long-term beneﬁcial effects
and are well tolerated, but that more longitudinal studies
of long duration need to be performed ( Fredriksen et al.,
2013 ). A second systematic review of both childhood and
adult studies found that ADHD individuals left untreated had
poorer long-term outcomes compared to treated individ-
uals in several major categories including academic, anti-
social behaviour, driving, non-medicinal drug use/addictive
behaviour, obesity, occupation, services use, self-esteem,
and social function outcomes, but that treatment did not
result in normalisation ( Shaw et al., 2012 ). In contrast, a
third systematic review of placebo-controlled discontinua-
tion studies and prospective long-term observational stud-
ies concluded that ADHD medication reduced ADHD symp-
toms and impairments, but that there was limited and in-
consistent evidence for long-term medication effects on im-
proved social functioning, academic achievement, employ-
ment status, and psychiatric comorbidity ( van de Loo-Neus
et al., 2011 ). Long-term placebo controlled trials would be
needed to allow deﬁnite conclusions, yet those are almost
impossible to conduct in real life. 
Pharmaco-epidemiological analyses of large-scale
databases, such as the national registers in Scandinavia,
are an alternative source of information about potential
(long-term) effects of ADHD medication on important
disease outcomes. A large register-based Swedish study
of adults with ADHD found that treatment with ADHD
medication signiﬁcantly reduces the risk for criminality
( Lichtenstein et al., 2012 ). Another Swedish register-based
study found that adult males with ADHD had a 58% reduced
risk of serious trafﬁc accidents in periods receiving treat-
ment, compared with periods without treatment ( Chang
et al., 2014a ). This was conﬁrmed in a recent study based
on individuals with ADHD from a large insurance claims
database, which found similar results in a US setting and
also among females ( Chang et al., 2017 ). Three addi-
tional pharmaco-epidemiological studies in children and
adolescents, using data from a Danish record linkage of
national registers ( Dalsgaard et al., 2015a ), a Hong Kong
electronic medical records database ( Man et al., 2015 ), and
a German insurance database ( Mikolajczyk et al., 2015 ),
have further extended such ﬁndings to these age groups.
A Danish register-based study showed that treatment with
ADHD medication reduced the risk for injuries by up to 43%
and emergency ward visits by up to 45% in children with
ADHD ( Dalsgaard et al., 2015a ). 
The pharmaco-epidemiological studies can also help clar-
ify the potential role of medication in causing morbidity.
For example, two register-based studies of adolescents and
adults with ADHD suggest that the co-occurrence of ADHD
and suicidal behaviour is due to shared familial risk fac-
tors ( Ljung et al., 2014 ), rather than to harmful effects
of ADHD medications ( Chen et al., 2014 ). A recent study
in a self-controlled case series also suggests that the ob-
served elevation of suicide attempt risk after medication
initiation is not causally related to the effects of stimu-
lants ( Man et al., 2017 ). In this study, the incidence of
suicide attempt was higher in the period immediately be-
fore the start of stimulant treatment. The risk remained
elevated immediately after the start of stimulant treat-Please cite this article as: B. Franke et al., Live fast, die young? 
the lifespan, European Neuropsychopharmacology (2018), httpsment and returned to baseline levels during continuation of
stimulant treatment. Furthermore, the apparent increase
in SUD risk in patients treated with stimulants, as discussed
above, seems to be due to familiality rather than medica-
tion effects. The previous concerns that stimulants could
lead to an increase in SUDs could not be conﬁrmed by the
pharmaco-epidemiological studies; these studies rather sug-
gest a reduction in SUDs following medical treatment of
ADHD ( Chang et al., 2014b; Skoglund et al., 2015 ). Another
register-based study from Sweden suggests that ADHD med-
ication does not increase the risk of later depression; also in
this case, medication was associated with a reduced risk for
subsequent and concurrent depression ( Chang et al., 2016 ).
7. Changes in cognitive and neuroimaging 
proﬁles across the lifespan 
In addition to a lifespan perspective on phenotypic and out-
come parameters in ADHD, also the dynamics across life in
biological markers and risk factors for the disorder need
to be understood better. ADHD is associated with several
cognitive impairments and brain alterations, both in child-
hood and in adulthood. Cognitive deﬁcits in ADHD encom-
pass both higher-level, effortful cognitive functions (e.g.,
inhibitory control, visuo-spatial and verbal working mem-
ory, sustained attention) and lower-level, potentially more
automatic cognitive processes (e.g., temporal information
processing and timing, vigilance, intra-individual variabil-
ity, reward processing) ( Karalunas et al., 2014; van Lieshout
et al., 2013; Willcutt et al., 2005 ). Meta-analyses of cogni-
tive studies in children establish ADHD to be associated with
poorer performance on tasks measuring inhibition, work-
ing memory, planning, and vigilance ( Huang-Pollock et al.,
2012; Willcutt et al., 2005 ). ADHD is also associated with
lower IQ scores ( Frazier et al., 2004 ). In addition, more re-
cent studies, including meta-analyses, indicate a strong as-
sociation of ADHD with reaction time variability (RTV), cap-
turing lapses in attention ( Frazier-Wood et al., 2012; Karalu-
nas et al., 2014; Kuntsi et al., 2010 ). Studies of adults with
ADHD reveal overall similar patterns of cognitive impair-
ments as found in children and adolescents ( Coghill et al.,
2014; Frazier-Wood et al., 2012; Hervey et al., 2004; Kuntsi
et al., 2010; Mostert et al., 2015; Mowinckel et al., 2015;
Sonuga-Barke et al., 2010 ). 
Structural and functional neuroimaging studies have doc-
umented abnormalities in brain anatomy and function in
individuals with ADHD ( Cortese et al., 2012; Frodl and
Skokauskas, 2012; Greven et al., 2015 ). Meta-analyses of
magnetic resonance imaging (MRI) studies show smaller vol-
umes in the ADHD brain, most consistently in the basal gan-
glia ( Frodl and Skokauskas, 2012; Hoogman et al., 2017 ).
This is important considering the key role of basal ganglia
in cognitive deﬁcits typically observed in ADHD, like reward
processing. In particular, smaller globus pallidus, putamen,
caudate nucleus, nucleus accumbens, amygdala, and hip-
pocampus, but also smaller total intracranial volume, were
found in children with ADHD, while in adults with ADHD,
the subcortical volume reductions were less pronounced
( Hoogman et al., 2017 ). A smaller anterior cingulateA review on the developmental trajectories of ADHD across 
://doi.org/10.1016/j.euroneuro.2018.08.001 
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(  ortex volume had been found earlier ( Frodl and 
kokauskas, 2012 ). One relatively large study further re- 
orted reductions in total brain and total grey matter vol- 
me in children, adolescents, and adults with ADHD, but no 
lterations in white matter volumes ( Greven et al., 2015 )
but also see Onnink et al., 2015 ). Functional abnormali-
ies are documented by a meta-analysis of 55 task-based 
unctional MRI (fMRI) studies ( Cortese et al., 2012 ), report-
ng that children with ADHD show a hypoactivation in the
ronto-parietal and ventral attentional networks involved 
n executive function and attention, and a hyperactiva- 
ion in the sensorimotor network and default-mode network 
DMN), involved in lower-level cognitive processes. Adult 
DHD is, instead, mostly associated with a hypoactivation 
n the fronto-parietal system and a hyperactivation in the 
isual network, dorsal attention network, and DMN ( Cortese 
t al., 2012 ). Atypical brain activity has further been re-
orted using EEG. For example, children and adults with 
DHD show alterations in event-related potential (ERP) ac- 
ivity of attentional allocation, inhibition, preparation and 
rror processing during cognitive tasks ( Albrecht et al., 
013; Cheung et al., 2016; Geburek et al., 2013 ), and in
uantitative EEG frequency power, mostly increased power 
f low frequency activity, during resting state ( Kitsune 
t al., 2015 ). 
Overall, cross-sectional studies indicate that many cog- 
itive and brain abnormalities are associated with ADHD in 
oth children and adults, although some differences have 
lso been observed between age groups. Looking at the de-
elopmental trajectories of cognitive, neuroanatomical and 
eurofunctional alterations in ADHD across the lifespan, it 
s important to examine whether cognitive and brain ab- 
ormalities (1) show an age-independent, consistent asso- 
iation with ADHD across the lifespan; (2) are predictors 
n childhood of later ADHD outcome; (3) can differentiate 
etween individuals with persistent ADHD (from here on 
ADHD persisters”) and individuals who have remitted from 
DHD over time (from here on “ADHD remitters”). 
As for point (1), prospective longitudinal studies with re- 
eated assessments of ADHD and cognitive measures are 
eeded to conﬁrm cross-sectional studies suggestive of sim- 
lar impairments across the lifespan. Such studies to date, 
ostly focusing on higher-level cognitive functions using 
Q tests, executive functioning and attentional tasks, show 
hat impairments tend to persist from childhood to adoles- 
ence and early adulthood in ADHD persisters ( Biederman 
t al., 2009; Cheung et al., 2016; Hinshaw et al., 2007;
cAuley et al., 2014 ). Fewer prospective longitudinal stud- 
es have investigated the developmental association be- 
ween ADHD and lower-level cognitive impairments, such 
s intra-individual variability measured with RTV. The three 
argest studies conducted to date on RTV, using motor tim-
ng and attentional paradigms, indicate persisting impair- 
ents both from middle to late childhood ( Vaughn et al.,
011 ) and from childhood to adolescence/early adulthood in 
DHD persisters ( Cheung et al., 2016; Thissen et al., 2014 ).
owever, in one of these studies the RTV impairment dur-
ng a motor timing task did not persist in the oldest group of
dults investigated, aged 22 years and above ( Thissen et al.,
014 ). Other longitudinal studies have used smaller samples 
 Doehnert et al., 2010; Doehnert et al., 2013 ), not distin-
uished between persisters and remitters ( Doehnert et al., Please cite this article as: B. Franke et al., Live fast, die young? 
the lifespan, European Neuropsychopharmacology (2018), https013; Mofﬁtt et al., 2015 ), or used different control groups
n childhood and at follow up ( McAuley et al., 2014 ), making
omparability to the above ﬁndings less clear. These stud-
es showed that deﬁcits in visual processing, vigilance, in-
ibition, and IQ may continue in adult age ( Mofﬁtt et al.,
015 ), while continuity of RTV impairments were observed
rom childhood to adulthood ( Doehnert et al., 2013 ), but
ot in adolescence ( Doehnert et al., 2010; McAuley et al.,
014 ). 
Among neuroimaging studies, longitudinal studies us- 
ng multiple assessments from childhood to adulthood are 
carce, and have mainly examined neuroanatomical abnor- 
alities with MRI. Available MRI studies consistently show 
hat smaller brain volumes and morphometric abnormal- 
ties persist over time in ADHD persisters re-assessed in
dolescence and early adulthood ( Castellanos et al., 2002;
haw et al., 2006; Shaw et al., 2013 ). For example, de-
elopmental abnormalities in cortical thinning have been 
bserved in the medial and dorsolateral prefrontal cortex 
components of networks supporting attention, cognitive 
ontrol, and the DMN), which resulted in a pattern of non-
rogressive deﬁcit in persistent ADHD from childhood to 
oung adulthood ( Shaw et al., 2013 ). Cortical thinning has
lso been found in ADHD in the medial and superior pre-
rontal and precentral regions, especially for ADHD individu- 
ls with worse clinical outcome: the ADHD group followed a
imilar developmental trajectory to control individuals from 
nitial assessments in childhood to ﬁnal assessments in ado-
escence, but with reductions of cortical thickness at all as-
essments ( Shaw et al., 2006 ). Atypical developmental pat-
erns of brain anatomy in individuals with persistent ADHD
ave been reported for subcortical regions and the cere-
ellum ( Castellanos et al., 2002; Mackie et al., 2007; Shaw
t al., 2014 ). Another study found divergent developmental
rajectories from age 4 through 19 years for ADHD persisters
nd control individuals in the basal ganglia from childhood
o adulthood: the ADHD group showed a smaller surface area
n childhood and a progressive atypical contraction com- 
ared to the control group, which instead showed an expan-
ion with age ( Shaw et al., 2014 ). A similar developmental
rajectory was found for cerebellar volume, where individ- 
als with persistent ADHD showed decreases in volume from
hildhood to adolescence/young adulthood, which were not 
bserved in control individuals ( Mackie et al., 2007 ). Further
RI studies have examined the development of the corpus
allosum and cortical surface area and gyriﬁcation ( Gilliam
t al., 2011; Shaw et al., 2011 ), but without distinguish-
ng between persistent and remittent ADHD at follow up,
hich makes the ﬁndings less informative. Little data exist
n the continuity of functional brain alterations in ADHD.
 small-scale longitudinal EEG study (n = 11 young adults
ith ADHD) reported that, among ERP impairments related 
o attentional allocation, inhibition, and response prepara- 
ion observed in childhood during a cued continuous per-
ormance test (CPT), only deﬁcits in response preparation 
ere associated with ADHD in adulthood ( Doehnert et al.,
013 ), without differentiating between persistent and re- 
ittent ADHD at follow up. 
The prediction of future ADHD outcome (remis- 
ion/persistence) based on early cognitive and neural im- 
airments measured in childhood within an ADHD sample 
point 2) is important for early identiﬁcation of those atA review on the developmental trajectories of ADHD across 
://doi.org/10.1016/j.euroneuro.2018.08.001 
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 risk for worse long-term outcomes ( van Lieshout et al.,
2013 ), with an eye on optimising treatment. Studies ex-
amining such prediction at short term indicate that impair-
ments in early childhood in executive functions, especially
inhibition and working memory, and in IQ predict ADHD
symptoms in later childhood ( Berlin et al., 2003; Brocki
et al., 2007; Campbell and von Stauffenberg, 2009; Kalff
et al., 2002 ), whereas RTV during a CPT does not ( Vaughn
et al., 2011 ). Studies investigating clinical outcomes of
ADHD persistence/remission with follow up in adolescence
and adulthood have obtained inconsistent results. More re-
cent follow-up studies of children with ADHD suggest that
RTV and working memory across different tasks in child-
hood may predict ADHD symptoms and/or functional im-
pairment in adolescents and young adults, even when con-
trolling for childhood ADHD symptoms ( Sjowall et al., 2015;
van Lieshout et al., 2016a ). This is inconsistent with re-
sults of studies examining persistence/remission of ADHD as
later outcome, which found no evidence for association of
aggregated measures of executive function, sustained at-
tention, inhibition, working memory, and RTV in childhood
and ADHD persistence/remission in adolescence and adult-
hood ( Biederman et al., 2009; Cheung et al., 2015b; Mick
et al., 2011 ). In a follow-up study, IQ was the only cognitive
measure in childhood which predicted later ADHD persis-
tence/remission, while measures of working memory (digit
span backward), sustained attention (omission errors), inhi-
bition (commission errors) and RTV from reaction-time and
go/no-go tasks did not ( Cheung et al., 2015b ). The predic-
tive value of IQ has been replicated in two other samples
of young adults ( Agnew-Blais et al., 2016; Gao et al., 2015 ),
but not in a third sample ( Francx et al., 2015b ). The only
study to date to examine the predictive value of childhood
brain activity on adult ADHD outcome indicated that resting-
state EEG measures in the theta and beta bands predict
ADHD persistence/remission ( Clarke et al., 2011 ), especially
in frontal regions implicated in ADHD. 
As for point (3), the identiﬁcation of cognitive and neural
processes underlying the trajectories of persistence and re-
covery from childhood-onset ADHD during the transition to
adulthood may further contribute to the prevention of nega-
tive long-term outcomes. It has been hypothesised that the
persistence of ADHD would be predicted by the degree of
maturation and improvement over time in higher-level cog-
nitive function, and lower-level cognitive functions would
be linked to the presence of ADHD in childhood irrespec-
tive of later clinical status ( Halperin and Schulz, 2006 ). In
a follow-up study of almost 100 individuals with childhood
ADHD assessed with both cognitive performance and EEG
actigraph measures (mean age at follow up 18.30, SD 1.60),
ADHD remitters did not differ from controls in higher-level
cognitive functions (e.g. working memory and commission
errors), but were still impaired in measures associated with
lower-level cognitive processes (RTV and perceptual sensi-
tivity) and ankle movement level ( Halperin et al., 2008 ).
The latter ﬁnding was supported by a second study in the
same sample, where RTV did not distinguish ADHD remit-
ters from persisters, both of whom were impaired compared
to controls ( Bedard et al., 2010 ). Other studies, however,
have not found an association between ADHD remission and
improvements in executive functioning ( Biederman et al.,
2009 ), interference control ( Pazvantoglu et al., 2012 ), andPlease cite this article as: B. Franke et al., Live fast, die young? 
the lifespan, European Neuropsychopharmacology (2018), httpsresponse inhibition ( McAuley et al., 2014 ). Working mem-
ory impairments in young adults diagnosed with ADHD in
adolescence compared to controls have also been observed
regardless of whether they still met an ADHD diagnosis
( Roman-Urrestarazu et al., 2016 ). Further studies found,
across different cognitive tasks, that cognitive- EEG mea-
sures of preparation, intra-individual variability (RTV), vig-
ilance, and error processing (mostly reﬂecting lower-level
cognitive functions) differentiated ADHD remitters from
persisters assessed in adolescence and young adulthood
( Cheung et al., 2016; James et al., 2017; Michelini et al.,
2016a ). Cognitive and brain activity measures of executive
control of inhibition, working memory, and conﬂict moni-
toring (largely reﬂecting higher-level cognitive functions)
were not sensitive to persistence/remission of the disor-
der ( Cheung et al., 2016; Michelini et al., 2016a ). As such,
these studies may suggest that (“lower-level”) preparation-
vigilance – instead of higher-level – cognitive functions may
be markers of ADHD recovery, following the symptom level
at follow up. 
Large-scale neuroanatomical studies also found evidence
of differences between ADHD persisters and remitters in
adolescents and adults in measures of brain volume and
structural connectivity. ADHD remitters have shown a slower
rate of cortical thinning from childhood to adulthood com-
pared to persisters, such that brain dimensions may be
more similar to those of control individuals in frontal and
parietal regions with age ( Shaw et al., 2006; Shaw et al.,
2013 ). Structural connectivity impairments in the left corti-
cospinal tract, implicated in the control of voluntary move-
ments, have been reported in adolescents and young adults
with childhood ADHD with persistent hyperactive-impulsive
symptoms compared to individuals with greater symptom
improvements over time and control individuals ( Francx
et al., 2015b ). In white matter tracts connecting vari-
ous regions related to sensorimotor and higher-level cog-
nitive functions, however, both ADHD persisters and remit-
ters showed impairments in adulthood compared to controls
( Cortese et al., 2013 ). Developmental pathways of brain
functioning may also show potential abnormalities, as sug-
gested by studies of adolescents with a diagnosis of ADHD
in childhood, but limited evidence is available to date. Two
studies of adolescents and young adults reported increased
resting-state fMRI connectivity in ADHD remitters compared
to controls in the executive control network, with inter-
mediate connectivity proﬁles in persisters ( Francx et al.,
2015a ), and increased EEG connectivity during an executive
control task in both ADHD remitters and persisters ( Michelini
et al., 2017 ). Other small-scale fMRI studies further suggest
that thalamic and cortical activation during response prepa-
ration ( Clerkin et al., 2013 ) and caudate activation during
working memory performance (Roman-Urrestarazu et al.,
2016) may be reduced in both ADHD persisters and remit-
ters. Instead, lower functional correlation between poste-
rior cingulate and medial prefrontal cortices (major com-
ponents of the DMN) during rest ( Mattfeld et al., 2014 ),
lower connectivity between the thalamus and prefrontal re-
gions during response preparation ( Clerkin et al., 2013 ), and
lower activations in areas of the prefrontal cortex involved
in reward processing ( Wetterling et al., 2015 ) may distin-
guish ADHD persisters from remitters and controls. A review on the developmental trajectories of ADHD across 
://doi.org/10.1016/j.euroneuro.2018.08.001 
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o  Overall, despite some inconsistencies between studies, 
ome convergence for cognitive and neuroimaging markers 
f ADHD persistence and remission is starting to emerge. For
xample, the majority of studies to date show that impair-
ents in executive function do not distinguish ADHD remit- 
ers and persisters ( Biederman et al., 2009; Cheung et al.,
016; McAuley et al., 2014 ; Michelini et al., 2016a , 2017 ;
azvantoglu et al., 2012 ). A particularly critical issue, likely 
xplaining some of the discrepancies across studies, is vari- 
bility in the way the persistence and remission are deﬁned,
s studies differ in the use of parent- or self-reports and
n whether functional impairment is taken into account at 
ollow-up assessments. However, there is a relatively low 
greement between self- and parent-reports of ADHD in 
dolescents and young adults, and objective cognitive and 
europhysiological data show lower agreement with ADHD 
utcome in adolescence and young adulthood based on self- 
eport than on parent-report ( Du Rietz et al., 2016 ). 
. The role of genetic and environmental 
isk factors and their interplay in ADHD across 
he lifespan 
hile investigations into the dynamics of cognitive and neu- 
oimaging markers across life have gained traction, the re- 
earch into lifespan aspects of underlying risk factors for 
DHD is still very much in its infancy. ADHD has a strong
enetic component. Family studies have consistently shown 
amilial clustering, with an ADHD relative risk of about 5- 
o 10-fold in ﬁrst-degree relatives of probands with ADHD 
 Biederman, 2005; Biederman et al., 1990; Franke et al.,
012 ). Twin studies show heritability estimates between 70% 
nd 80%, and the underlying genetic architecture of ADHD 
ppears similar across the different core symptom dimen- 
ions and gender ( Faraone et al., 2005; Larsson et al., 2014;
ikolas and Burt, 2010 ). Consistent evidence supports sta- 
ility in the ADHD heritability across the lifespan estimated 
sing the same informant across ages and cross-informant 
pproaches ( Brikell et al., 2015; Chang et al., 2013; Kuntsi
t al., 2005 ). 
Given the multifactorial, polygenic nature of ADHD, ge- 
etic research has mainly focused on common variants 
hrough hypothesis-driven candidate gene association stud- 
es (CGAS) and genome-wide association studies (GWAS) 
ith case-control or family-based designs. These designs 
onsist on observational studies in which the frequencies 
f speciﬁc common genetic variants within candidate genes 
or ADHD or a genome-wide set of polymorphisms are com- 
ared between affected (cases) and unaffected (controls) 
ndividuals or between affected subjects and their relatives. 
everal linkage studies have also been performed. They 
llow genetic mapping of complex traits showing famil- 
ar aggregation by assessing the co-segregation of the dis- 
ase phenotype with sequence variants across the genome. 
ore recently, genetic studies in ADHD have also focused 
n rare variation (allele frequency < 0.05) through copy- 
umber variant (CNV) analyses, which inspect alterations in 
enomic segments of more than 1Kb in length, and exome 
hip analysis and whole-exome sequencing, targeting point 
utations or small indels. These investigations have shown Please cite this article as: B. Franke et al., Live fast, die young? 
the lifespan, European Neuropsychopharmacology (2018), httpsonverging evidence for common biological pathways un- 
erlying ADHD, which highlights that both common and rare
enetic variants account for a signiﬁcant proportion of the
enetic susceptibility to the disorder ( Martin et al., 2015b;
tergiakouli et al., 2012; Zayats et al., 2016 ). 
To date, seven genome-wide linkage scans have been 
erformed in ADHD. Although very little overlap was ob-
erved between analyses, different genetic loci potentially 
nvolved in ADHD have been found on chromosomes 5p13,
4q12, and 17p11, and a meta-analysis of ADHD linkage
tudies conﬁrmed a locus on chromosome 16 ( Zhou et al.,
008 ). Only few positional candidate genes have, however,
een identiﬁed from these linkage scans, e.g. DIRAS2 ( Reif
t al., 2011 ) and LPHN3 ( Arcos-Burgos et al., 2010 ). Also,
lthough hundreds of CGAS have been reported, only a few
ndings have been consistently replicated across studies. 
hese studies have focused primarily on genes involved in
eurotransmission, particularly in the monoaminergic path- 
ays. Serotonin and dopamine receptors and transporters 
re the most extensively studied and replicated across pop-
lations ( Franke et al., 2012; Gizer et al., 2009; Hawi et al.,
015 ). Almost all studies were performed in children, and
one of the resulting candidate genes can be considered as
stablished. One of the few genes tested thoroughly in both
hildren and adults is the dopamine transporter, and intrigu-
ngly, opposite alleles were associated with childhood and 
dulthood ADHD ( Franke et al., 2010 ). 
GWAS on ADHD have been completed in nine indepen-
ent datasets ( Anney et al., 2008; Franke et al., 2009; Hin-
ey et al., 2011; Lasky-Su et al., 2008; Mick et al., 2010;
eale et al., 2008; Sanchez-Mora et al., 2015; Stergiak-
uli et al., 2012; Yang et al., 2013; Zayats et al., 2015 ),
hree of them focusing on the persistent form of the dis-
rder ( Lesch et al., 2008; Sanchez-Mora et al., 2015; Za-
ats et al., 2015 ). Although none of them, nor two meta-
nalyses on several of these datasets ( Neale et al., 2010;
an Hulzen et al., 2016 ), reported genome-wide signiﬁ-
ance, the integration of top ﬁndings from the different
tudies showed enrichment of genes related to neurobi- 
logical functions potentially relevant to ADHD, such as 
eurite outgrowth, central nervous system development, 
euronal development, differentiation and activity, neuron 
igration, synaptic transmission, axon guidance, Calcium- 
ctivated K + channels, FGFR ligand binding, and activa- 
ion or potassium channels, among others ( Mooney et al.,
016; Sanchez-Mora et al., 2015; Yang et al., 2013; Zayats
t al., 2015 ). For the ﬁrst time, a very recent GWAS meta-
nalysis in 20,183 ADHD cases and 35,191 controls, includ-
ng children and adults from 12 datasets, reported genome-
ide signiﬁcant hits in 12 independent loci that include
enes involved in neurodevelopmental processes, such as 
OXP2 or DUSP6, and evolutionarily conserved genomic re- 
ions ( Demontis et al., 2017 ). Limited overlap exists be-
ween results of GWAS and previous CGAS or linkage studies,
nd a separate analysis for the persisting versus remitting
orms of ADHD is still lacking. Thus, the genetic architecture
nderlying the lifespan trajectory of ADHD is still largely
bscure. 
Although each of the ADHD-associated variants appears 
o account for a small proportion of the variance in ADHD
ymptoms, SNPs were estimated to account for 10% to 28%
f the heritability of the disorder ( Anttila et al., 2018; De-A review on the developmental trajectories of ADHD across 
://doi.org/10.1016/j.euroneuro.2018.08.001 
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 montis et al., 2017; Cross-Disorder Group of the Psychiatric
Genomics Consortium, 2013 ). These studies also highlight
substantial genetic overlap between the ADHD genetic back-
ground and ADHD-related traits, other psychiatric and neu-
rological disorders or behavioural-cognitive traits, includ-
ing positive correlations with major depressive disorder, mi-
graine, obesity, and smoking, as well as negative correla-
tion with educational outcomes and childhood IQ ( Anttila
et al., 2018; Demontis et al., 2017; Cross-Disorder Group
of the Psychiatric Genomics Consortium, 2013 ). In addi-
tion to GWAS, under the hypothesis that ADHD can be ex-
plained by the ensemble of genetic markers of small ef-
fect, polygenic risk score approaches have emerged to as-
sess whether, when considered “en masse”, ADHD com-
mon risk variants also contribute to different ADHD-related
phenotypes. These ﬁndings provided evidence that poly-
genic risk for ADHD predicts hyperactivity-impulsivity and
inattention traits in the general population, as well as
autism spectrum disorder-related traits and conduct disor-
der ( Hamshere et al., 2013; Martin et al., 2014 ). Again, none
of these studies considered the lifespan perspective. 
Research on rare variants involved in ADHD points at a
greater burden of large CNVs ( > 100 kb or > 500 kb) in chil-
dren or adolescents with the disorder ( Martin et al., 2015b;
Stergiakouli et al., 2012; Williams et al., 2010 ) and in adults
with ADHD ( Lesch et al., 2011; Ramos-Quiroga et al., 2014 ),
and also shows enrichment of ADHD-related CNVs at loci
previously associated with neurodevelopmental disorders,
such as autism and schizophrenia ( Thapar et al., 2016 ). Ad-
ditional evidence from exome sequencing supports the in-
volvement of rare variants (minor allele frequency (MAF)
of < 1%) in individuals with ADHD at different age ranges.
Although the study of a pedigree with several affected indi-
viduals failed to identify causal rare variants for ADHD ( Lyon
et al., 2011 ), rare de novo missense variants were found in
brain-expressed genes in children with sporadic ADHD ( Kim
et al., 2017 ) and novel putative functional rare variants in
the BDNF were identiﬁed in children and adolescents with
ADHD ( Hawi et al., 2017 ). Rare missense and disruptive vari-
ants were also identiﬁed through whole-exome sequencing
or exome chip analyses in adult ADHD ( Zayats et al., 2016 ). 
Overall, while it is well-established that ADHD is a highly
heritable condition with a complex genetic architecture,
more research is needed to identify the speciﬁc genetic un-
derpinnings of the disorder and its persistence into adult-
hood. In addition to risk factors stably involved in ADHD
throughout the lifespan, the susceptibility to ADHD persis-
tence may be a dynamic process, with speciﬁc genetic in-
ﬂuences acting at different developmental stages ( Chang
et al., 2013; Kuntsi et al., 2005 ). Thus, different sets of
genes, and even different alleles at a given risk locus,
could be involved in the differentiation between persist-
ing and remitting forms ( Franke et al., 2012; Kuntsi et al.,
2005 ) and inﬂuence the disorder and associated cognitive
deﬁcits differently according to age (gene by age interac-
tions) ( Thissen et al., 2015 ). To our knowledge, all genetic
studies that have approached the problem of the potential
differential genetic load of ADHD in persisting versus remit-
ting cases so far have simply compared children and adults
with ADHD. Although these reports describe genetic speci-
ﬁcities in age groups ( Franke et al., 2012; Ribases et al.,
2009 ), they may be subject to false-negative ﬁndings, asPlease cite this article as: B. Franke et al., Live fast, die young? 
the lifespan, European Neuropsychopharmacology (2018), httpsthe comparison is between persistent cases and a sample
of children likely to be a heterogeneous group of individu-
als in which the disorder will persist or remit into adulthood.
Longitudinal designs constitute an alternative approach that
may provide insights into the role of genes in the persistence
of ADHD across the lifespan. 
9. Environmental risk factors and 
gene-by-environment (GxE) interactions 
One explanation for the discrepancy between high heri-
tability estimates for ADHD and the scarcity of replicable
gene-disorder associations could be that expression of spe-
ciﬁc genes is conditional on epigenetic programming. Such
programming is inﬂuenced by both genetic code and envi-
ronment of an individual, although the contribution of the
environment to the aetiology of the disorder seems to be
lower than that of heritable factors (with around 22% of
ADHD variance explained by environmental factors ( Faraone
et al., 2005; Nikolas and Burt, 2010 ). The concept of gene-
by-environment (GxE) interaction is in line with epidemi-
ologic studies revealing – in addition to the genetic risk
– associations between ADHD and environmental adversity
including pre- and peri-natal risk factors (maternal stress,
smoking or alcohol consumption during pregnancy, low birth
weight, prematurity), environmental toxins (organophos-
phates, polychlorinated biphenyls, lead), unfavourable psy-
chosocial conditions (severe early-childhood deprivation,
maternal hostility) and nutritional factors ( Faraone et al.,
2015 ). It is likely that the heritability estimates for ADHD
based on twin research are inﬂated by GxE interactions
( Purcell, 2002 ), which may also account in part for some in-
consistent ﬁndings of genetic association. Accordingly, sev-
eral studies support the inﬂuence of genetic variants on ef-
fects of environmental risk factors for ADHD ( Franke and
Buitelaar, 2018 ), with interactions found e.g. between DRD4
and exposure to prenatal smoking ( Pluess et al., 2009 ),
SLC6A3/DAT1 and maternal use of alcohol during pregnancy
( Brookes et al., 2006 ), institutional deprivation ( Kumsta
et al., 2010 ) psychosocial adversity ( Laucht et al., 2007 ),
SLC6A4 / 5HTT and psychosocial stress ( Muller et al., 2008 ),
MAOA and negative parenting behaviour ( Li and Lee, 2012 ),
and ADGRL3 / LPHN3 and maternal stress during pregnancy
( Choudhry et al., 2012 ). 
Most of the environmental factors that are considered
to increase ADHD and comorbid disorder susceptibility act
prenatally, suggesting that exposure to environmental risks
would have more impact if occurring during a critical devel-
opmental period (for a review, see Mill and Petronis, 2008;
Spiers et al., 2015 ). Although it should be kept in mind
that risk factors associated with a disorder are not neces-
sarily causal ( Rutter, 2007 ), there is now evidence to sug-
gest that early-life exposure to smoking, alcohol, and illicit
drug use as well as suboptimal nutrition or the changes in
microbiome composition can permanently affect transcrip-
tional regulation through epigenetic alterations, and this is
thought to contribute to the long-lasting consequences on
offspring health ( Loche and Ozanne, 2016 ). Foetal, perina-
tal, and adolescent periods are the developmental periods
of highest phenotypic plasticity, contributing largely to de-
velopmental programming, and the epigenome is sensitiveA review on the developmental trajectories of ADHD across 
://doi.org/10.1016/j.euroneuro.2018.08.001 
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 o environmental challenges applied during these critical 
indows of development. Various risk factors that usually 
ccompany behavioural disorders seem to be involved in 
hese epigenetic modiﬁcations, especially early-life stress 
ncluding trauma, abuse, and neglect. As there is prelim- 
nary evidence for a role of diet or lifestyle in ADHD, di-
tary changes, like the elimination or addition of certain 
utrients, are being explored as a possible way to modify
ymptoms ( Lange, 2017 ). While nutrition and lifestyle, as 
ell as environmental adversity in general, are thought to 
e potent epigenetic modiﬁers, complex interactions among 
ood components, environmental toxins, or drugs of abuse 
nd DNA methylation, histone modiﬁcations and epigenetic- 
elated RNA-based mechanisms lead to dynamic regulation 
f gene expression that controls the neural cell phenotype 
nd brain function ( Robison and Nestler, 2011 ). A consid-
rable challenge to research on the human epigenome is, 
owever, the tissue and cell speciﬁcity of epigenetic modiﬁ- 
ation. As brain tissue from ADHD patients is not available,
esearch on epigenetic mechanisms has to rely on acces- 
ible material (e.g. blood or buccal cells) as a proxy for
he brain. Nevertheless, there is evidence that epigenetic 
esearch in humans is feasible, and ﬁrst studies, focusing 
n both potential risk genes ( Heinrich et al., 2017; van Mil
t al., 2014 ) and the entire epigenome ( Walton et al., 2017;
ilmot et al., 2016 ), conﬁrm links between epigenetic mod-
ﬁcation of genes and ADHD. 
A pioneering study on ADHD epigenetics was a whole- 
pigenome screening of two independent samples in boys 
ith ADHD by Wilmot et al. (2016) . It provided evidence
or an involvement of gene-sets and pathways related to in-
ammatory processes as well as modulation of monoamine 
nd cholinergic transmission. Two genes, encoding VIPR2 
nd MYT1L (mutations cause intellectual disability, autism), 
ere conﬁrmed in the replication sample. Walton et al. 
2017) reported that DNA methylation at birth differenti- 
ted ADHD-related trajectories in a population-based co- 
ort across multiple genomic locations implicating e.g. 
enes coding for SKI (involved in neural tube development), 
NF544 (previously linked to ADHD), and ST3GAL3 (muta- 
ions cause intellectual disability), although none of these 
enes maintained an association with ADHD trajectories at 
ge 7 years. Together, these studies – some in small co- 
orts – provide initial insight into the epigenetic background 
f ADHD, underscoring the relevance of differential DNA 
ethylation in genes related to monoaminergic, cholinergic 
nd GABAergic transmitter system function and neurodevel- 
pmental processes that play a role in the formation, mat-
ration, and plasticity of distinct brain networks. 
0. Discussion and future directions 
n this review, we aimed to provide an overview of the cur-
ent knowledge about ADHD across the lifespan. We covered 
he major phenotypic and biological issues related to this 
isorder, which is a prominent cause of psychiatric morbid- 
ty and impairment in both childhood and adulthood. We dis- 
ussed developmental trajectories in core phenotype deﬁni- 
ion, comorbidity, cognitive and brain structural/functional 
arkers, as well as treatment trajectories, outcomes, and 
enomic markers. Our review shows that beyond research Please cite this article as: B. Franke et al., Live fast, die young? 
the lifespan, European Neuropsychopharmacology (2018), httpsnto the core symptoms of ADHD, information is still very
atchy, and relatively little is known about developmental 
rajectories from childhood into adulthood for most of the
ssues of interest. This deﬁnes priorities in the coming years
or research of phenotypic issues, treatment and prediction 
f outcome, as well as our understanding of the biological
nderpinnings of ADHD. 
In all areas of our investigation into the ADHD literature,
he absence of studies in the elderly is highly apparent. Old
ge is the current blind spot of ADHD research, which has
o be factored in when interpreting all the data presented
bove. This lack of knowledge limits the possibility to per-
orm a review of the complete lifespan, as most available
tudies deal with ADHD in children – even 50 years after the
rst studies showed that ADHD also exists in adults and can
ontinue from childhood to adulthood ( Wood et al., 1976 ).
eyond mid-adulthood, hardly any information on ADHD can 
e found. 
An important additional caveat of current literature is the
imited availability of longitudinal studies with a careful and
epeated, detailed characterisation of participants across 
ifferent phases of the lifespan regarding terms of deep
linical phenotyping as well as biomarkers. Such work is es-
ential to chart the trajectory of ADHD symptoms over the
ifetime and will answer important questions about the in-
erplay of ADHD disposition with environmental conditions. 
hose studies are urgently needed for clinical cohorts as 
ell as the general population, and should include broad
ssessment batteries of disease phenotypes and treatments, 
uantitative behavioural measures, cognitive tasks and neu- 
oimaging, as well as repeated biomaterial collection. Some 
xisting population studies, like MoBA ( Magnus et al., 2016 ),
LSPAC ( Martin et al., 2015a ), the Dunedin Study ( Mofﬁtt
t al., 2015 ), and LifeLines ( Stolk et al., 2008 ) and in partic-
lar more recent large-scale initiatives like the UK Biobank
 Clarke et al., 2017 ) may provide a template for such work.
ressing questions for research in such cohorts can be de-
ned in terms of the phenotypic deﬁnition of ADHD: 
1) Only in such longitudinal cohorts the relation of apparent
adult-onset ADHD to the neurodevelopmental form of the 
disorder can be deﬁned: are these different disease en-
tities, with different aetiologies and (co)morbidity pro- 
ﬁles, or can they be different subtypes/presentations of 
the same, overarching disorder? To study this question, 
one needs also to enrol children with mental disorders
other than ADHD and sub-threshold ADHD symptoms. 
2) Is the persistent form of ADHD really persistent, or do
ADHD symptoms over time ﬂuctuate with varying inten- 
sity, thus creating suffering and burden only in speciﬁc 
life phases, e.g. characterised by high life stress or high
demands for self-management ( Grevet et al., 2006 )? Per-
sistent ADHD, after all, might not be as trait-like as it is
assumed ( Karam et al., 2017 ), which might obscure its
detection. 
3) There are only a few studies on ADHD remitters. How-
ever, this particular group brings up important questions: 
which are the resilience factors that protect against per-
sistence? Are there differential genetic factors that have 
a role in remission versus persistence? What about en-
vironmental factors and GxE phenomena? What is the 
brain’s developmental trajectory? Clues that help to an- A review on the developmental trajectories of ADHD across 
://doi.org/10.1016/j.euroneuro.2018.08.001 
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 swer these questions might translate into clinical prac-
tice to improve the outcome of patients, and thus ac-
cording studies should be prioritised. 
4) Developmental trajectories of comorbidity proﬁles and
cognitive functioning across the lifespan: as we have
reviewed above, ADHD is characterised by extensive
comorbidity in childhood and adulthood. However, the
comorbidity proﬁles of child and adult ADHD change
and only partly overlap. Clinical longitudinal studies are
needed to understand onset and changes in comorbid-
ity. Recent ﬁndings from large genetic studies as well
as register-based studies show that comorbidity is of-
ten based on shared familial and genetic factors (e.g.
Ghirardi et al., 2017; Cross-Disorder Group of the Psy-
chiatric Genomics Consortium, 2013 ). 
5) Cognitive functioning, brain structure/function, and the
contribution of genetic and environmental risk factors
across the lifespan: overall, cognitive and neuroimag-
ing studies to date converge in indicating that most im-
pairments persist when ADHD persists from childhood to
later assessments. Yet, most existing studies are cross-
sectional and have used samples in young or middle
adulthood only. Large longitudinal studies are needed,
also including assessments of older age groups, to fully
characterise the developmental trajectories of ADHD-
related cognitive and brain impairments across the lifes-
pan. In addition, since some of the cognitive and neural
alterations observed in ADHD are non-speciﬁc, but rather
shared with other disorders (e.g. autism and bipolar dis-
order) Rommelse et al., 2011; Michelini et al., 2016b ,
2018 ), future research should take into account comor-
bid symptoms when examining the persistence of impair-
ments. In terms of genetic and environmental risk fac-
tors, we need to clarify the contribution of individual
factors across the lifespan. Also, recent work indicates
that there is limited speciﬁcity in the genetic contribu-
tion to ADHD ( Demontis et al., 2017 ) and other psychi-
atric disorders (e.g. Anttila et al., 2018 ). In fact, it ap-
pears that part of the genetic contribution to psychiatric
disorders is due to a general psychopathology factor (or
“p-factor”) (e.g. Neumann et al., 2016 ). How these ﬁnd-
ings relate to comorbidity and disease outcome in ADHD
is another important area of future research. 
6) Finally, prediction of disease outcome is an area of re-
search that can directly inﬂuence treatment decisions
in daily clinical practice. Cognitive, electrophysiologi-
cal, and neuroimaging markers associated with childhood
ADHD persist into adulthood, but show variable trajecto-
ries reﬂecting both delayed maturation and within-group
differences. Findings suggest a pattern of corresponding
biomarkers that predict remission versus persistence of
ADHD symptoms in adolescence and adulthood. However,
to move forward towards potential clinical applications
of these markers as a means to identify those childhood
and adolescent cases with ADHD that are at high risk for
persistent ADHD, prediction parameters at the individual
level have to be examined. Importantly, the predictive
power/accuracy of currently identiﬁed biomarkers is in-
dividually low. Future studies should therefore explore
whether combining markers from different cognitive and
imaging domains as well as (epi)genetic approaches may 
Please cite this article as: B. Franke et al., Live fast, die young? 
the lifespan, European Neuropsychopharmacology (2018), httpsimprove prediction. Future longitudinal and clinical stud-
ies should address these questions while using sophisti-
cated approaches, like normative modelling and multi-
variate pattern recognition ( Wolfers et al., 2015 ). While
ADHD outcome is mostly deﬁned as persistence of the
clinical diagnosis or symptoms, studying outcomes re-
lated to educational performance and adulthood func-
tionality might also be of importance for the quality of
life of patients. 
The questions raised above reach far beyond mere aca-
demic interest, as respective answers will immediately im-
pact on ADHD treatment. For instance, timing of treatment
is an essential issue, as we are only about to begin to un-
derstand the long-term effects of pharmacological ADHD
treatment regarding outcome (educational, socio-economic
and, most importantly, health, also regarding comorbid con-
ditions). To address this, however, we need granular lon-
gitudinal studies, initiated in childhood and followed up
long-term. A tightly linked question is how adolescents can
be kept in treatment – or at least in mental health ser-
vices – during the transitional period, thereby preventing
the “transition gap” and potentially the development of co-
morbid disorders such as depression or SUD. On the other
hand, a waxing and waning pattern of ADHD symptoms and
related burden of disease in speciﬁc life situations might
allow for interval treatment, and especially addressing the
role of resilience in the interaction of life stress and ADHD
disposition might unleash a huge potential for psychother-
apy. More research into persistence within and across differ-
ent age-ranges is therefore urgently needed. Beyond these
“traditional” approaches, novel treatments, such as non-
invasive brain stimulation, neurofeedback, and nutritional
interventions, should be assessed for their lifespan effects.
Within this framework of long-term treatment effects, pre-
diction has also to be factored in. If ADHD persistence or
development of comorbidity could reliably be foreseen, this
would dramatically alter the way ADHD is treated over the
lifespan, opening up a perspective for precision medicine.
Most likely, predictive approaches will be multimodal (in-
tegrating genetics, proteomics, neuroimaging, and granular
ecological momentary assessment (EMA) of behavioural pat-
terns), but also require biomarker studies on disease trajec-
tories of the lifespan. 
In terms of understanding the risk factors underlying
ADHD, which might be linked to such predictive markers,
important progress has been made in the areas of environ-
mental and genetic risk factors in recent years. In particular,
the latter one has been enabled by technological progress
as well as the formation of large, international collabo-
rations, like the Psychiatric Genomics Consortium ( Cross-
Disorder Group of the Psychiatric Genomics Consortium,
2013 ). Still, acknowledging the small effect sizes of most in-
dividual genetic risk factors for ADHD, much larger samples
will be needed in the future to identify a sufﬁcient number
of the underlying genes to tease out the most strongly in-
volved (and potentially druggable) biological pathways con-
tributing to ADHD. An excellent development in this area
is the increasing availability of biosamples linked to popu-
lation registers, starting with the Danish iPSYCH Initiative
( Demontis et al., 2017 ). This will likely allow us to reachA review on the developmental trajectories of ADHD across 
://doi.org/10.1016/j.euroneuro.2018.08.001 
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mample sizes of over 100,000 patients in the next 5 years.
n addition, the recent demonstration of the strong genetic 
verlap of clinically diagnosed ADHD and population ADHD 
cores ( Demontis et al., 2017 ) will contribute to a strong rise
n sample availability and the number of ADHD loci identi-
ed in the coming years. Critical windows for environmental 
isk factors across the lifespan are already understood quite 
ell. However, while we know that partly different sets of
enetic factors contribute to ADHD onset and persistence 
 Chang et al., 2013 ), the lifespan perspective has yet to be
aken in genetics research and is only rarely addressed. The 
vailability of register-data and population samples also in- 
reases our prospects of improving our knowledge about dif- 
erences in the contribution of different genetic risk factors 
o ADHD across the lifespan. 
More than 1000 genes/genomics regions may contribute 
o neurodevelopmental disorders like ADHD. Many of those 
enes/regions can be expected to contain several inde- 
endent risk loci. How informative the identiﬁcation of all 
f those will be for our understanding of disease mecha-
isms and potential new treatment routes has recently been 
uestioned by a paper discussing “omnigenic” diseases and 
raits ( Boyle et al., 2017 ). In their paper, the authors ar-
ue that the most informative genetic markers may come 
rom studies of rare genetic variants, as more or less all
enes expressed in a certain tissue can be expected to make
mall contributions to a disease related to this tissue ( Boyle
t al., 2017 ). The role of rare variants in ADHD across the
ifespan is currently virtually unexplored (although an ex- 
me sequencing study is in the ﬁnal stages of analysis), 
nd awaits the upcome of affordable genome sequencing 
pproaches. 
Lastly, epigenetics research offers great opportunities 
o integrate genetic and environmental risk in ADHD. Also 
ere, only ﬁrst steps have been made towards exploring 
he involvement of aberrant epigenetic patterning in ADHD. 
s discussed above, these steps are hampered by the tis-
ue speciﬁcity of epigenetic modiﬁcations, leading to un- 
ertainty about the predictive value of proxy tissues like 
lood and saliva, which are the only accessible tissues 
vailable in large samples. Changes in epigenetic proﬁles 
ver time, like those needed to explore lifespan changes 
n the ADHD phenotype/outcome, might be more infor- 
ative in those proxy tissues, but this hypothesis awaits 
esting. 
In conclusion, ADHD is the prototypic example of a 
eurodevelopmental disorder starting early in life and 
eveloping with a highly variable trajectory. While in 
ome cases it might be the entry point into a negative,
urdensome trajectory, other patients may remit and even 
ransform some deﬁcits into adaptive behaviours, living 
ighly successful lives. The latter suggests that there 
s potential for improvement in many ADHD patients, if 
ecognised early on and receiving optimal treatment. To 
larify the course, to identify those at risk of unfavourable
utcome and to provide tailored treatment, longitudinal, 
ranular, and multimodal studies are clearly needed. While 
e appreciate that this poses a challenge, we are conﬁdent
hat such an endeavour would – just like the ﬁght against 
IV three decades ago – pay off in every respect to improve
he life of many patients. t
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